MedTrace Logo

Ginsenoside-Rd for Acute Ischemic Stroke

NCT00591084 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 199

Last updated 2010-09-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of ginsenoside-Rd for acute ischemic stroke.

Conditions

Interventions

DRUG

ginsenoside-Rd 10 mg

infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days

DRUG

placebo

infusion placebo (group B)once a day and continued for 14 days

DRUG

ginsenoside-Rd 20mg

infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days

Sponsors & Collaborators

  • Xijing Hospital

    lead OTHER

Principal Investigators

  • Gang Zhao, MD · the Department of Neurology , Xijing Hospital;

  • Xuedong Liu, MD · the Department of Neurology, Xijing Hospital;

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-09-30
Primary Completion
2006-06-30
Completion
2006-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00591084 on ClinicalTrials.gov